Singapore, May 12 -- Singapore-based startup Nanyang Biologics (NYB) and Precisya Global Inc (PGI), based in the US, have announced a strategic collaboration to leverage technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI's genomic big data analytics with NYB's natural compound libraries and artificial intelligence (AI) capabilities.

The collaboration will leverage DTIGN (Drug-Target Interaction Graph Neural Network), NYB's proprietary AI model that has demonstrated a 27.03% improvement in prediction accuracy over leading methods.

DTIGN significantly enhances the identification of active compounds...